Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

N4 Pharma Plc (N4P)

Price 0.60p on 22-10-2024 at 16:30:01
Change 0.00p 0%
Buy 0.65p
Sell 0.55p
Buy / Sell N4P Shares
Last Trade: Buy 246.00 at 0.65p
Day's Volume: 589,363
Last Close: 0.60p
Open: 0.60p
ISIN: GB00BYW8QM32
Day's Range 0.60p - 0.60p
52wk Range: 0.412p - 1.30p
Market Capitalisation: £2m
VWAP: 0.596444p
Shares in Issue: 395m

Recent Trades History N4 Pharma Plc (N4P)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 246 0.65p Ordinary
13:46:49 - 22-Oct-24
Buy* 460 0.65p Ordinary
13:09:54 - 22-Oct-24
Buy* 82,216 0.6033p Ordinary
13:09:50 - 22-Oct-24
Buy* 296,852 0.6033p Ordinary
13:01:58 - 22-Oct-24
Buy* 100,000 0.604p Ordinary
12:38:10 - 22-Oct-24
Buy* 307 0.65p Ordinary
10:22:23 - 22-Oct-24
Buy* 1,076 0.65p Ordinary
09:56:45 - 22-Oct-24
Buy* 386 0.65p Ordinary
08:46:10 - 22-Oct-24
Buy* 307 0.65p Ordinary
08:35:44 - 22-Oct-24
Sell* 100,488 0.558p Ordinary
08:15:30 - 22-Oct-24

Share Price History for N4 Pharma Plc

Time period:
to
Date Open High Low Close Volume

Share News for N4 Pharma Plc

EARNINGS: Metals One advances Black Schist, N4 generates revenue

24th Sep 2024 15:01

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: N4 Pharma celebrates chemistry work update on Nuvec

20th Aug 2024 11:52

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology Nuvec - Notes SRI International has successfully completed the chemistry work and shown that a fox three molecular guidance system can be added to Nuvec without altering its loading capability. Chief Executive Nigel Theobald says: "This is an exciting development for us as it clearly shows that Nuvec is capable of targeting specific cells via the addition of a relevant ligand, something the industry is actively looking for. We will now start working on a combined marketing pitch deck allowing SRI and N4 Pharma to present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs." N4 Pharma says the next step is to show that small interfering RNA still retains its functionality in the target cell. Read More

AIM WINNERS & LOSERS: Shuka Minerals down on CLN drawdown

20th Aug 2024 10:24

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

TRADING UPDATES: Topps Tiles sales dip; Physiomics completes placing

3rd Jul 2024 12:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

N4 Pharma raises GBP630,000 to advance primary work streams

7th Jun 2024 12:32

(Alliance News) - N4 Pharma PLC on Friday said it has raised GBP630,000 through a placing and subscription of shares. Read More

FTSE 100 Latest
Value8,306.54
Change-11.70

Login to your account

Forgot Password?

Not Registered